Draft:Cessatech
Submission declined on 24 September 2024 by Ibjaja055 (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|
Submission declined on 23 September 2024 by SafariScribe (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by SafariScribe 32 hours ago.
|
Submission declined on 23 September 2024 by Frost (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies. Declined by Frost 33 hours ago. |
- Comment: Your draft should meet WP:ORGCRIT. Sources should also meet the WP:GOLDENRULE. Safari ScribeEdits! Talk! 09:15, 23 September 2024 (UTC)
Cessatech A/S is a Danish pharmaceutical company based in Copenhagen, founded in 2020. The company focuses on developing treatments for pediatric patients, particularly in the area of acute pain management.
History
[edit]Cessatech was established in 2020 with the aim of addressing unmet needs in pediatric pain management.[1][2] The company's research and development efforts are centered on creating therapies suitable for children, with an emphasis on non-invasive delivery methods.
Products Under Development
[edit]CT001
[edit]CT001 is an intranasal analgesic spray being developed for managing acute pain in children. It combines ketamine and sufentanil and is designed for needle-free administration.[3] As of 2024, CT001 was in the pivotal stage of clinical development.
CT002
[edit]CT002 is a nasal spray in early stages of development, intended to sedate children during medical procedures such as MRI scans.[4] In 2024, the European Medicines Agency (EMA) agreed to a Pediatric Investigation Plan (PIP) for CT002.[5]
Clinical Trials
[edit]Cessatech has conducted several clinical trials to evaluate the efficacy and safety of CT001:
- Study 0201: A 2014 study on CT001's use for procedural pain in children.[6]
- Studies 0207 and 0208: Presented at the 2024 Population Approach Group in Europe (PAGE) conference, these studies involved pharmacokinetic and pharmacodynamic modeling of CT001.[7][8]
- Registry Study 0203: A 2024 study exploring the safety and tolerability of S-ketamine and sufentanil nasal spray in pediatric patients.[9]
Regulatory Affairs
[edit]The EMA agreed to Pediatric Investigation Plans for both CT001 (in 2019) and CT002 (in 2023), supporting their development for pediatric use.[10][11]
References
[edit]- ^ "Inhalationsbedøvelse til børn". Rigshospitalet (in Danish). Retrieved 23 September 2024.
- ^ "Cessatech A/S Member Profile". Dansk Biotek. Retrieved 23 September 2024.
- ^ "Cessatech completes pivotal study with positive results". MedWatch (in Danish). 5 June 2024. Retrieved 23 September 2024.
- ^ "Cessatech advances CT002 after EMA agreement". MedWatch (in Danish). 24 July 2024. Retrieved 23 September 2024.
- ^ "Cessatech receives EMA approval for PIP on CT002". MedWatch (in Danish). 12 April 2024. Retrieved 23 September 2024.
- ^ Nielsen, B.N. (2014). "Nasal ketamine and sufentanil for pain relief in children during wound dressing changes". Paediatric Anaesthesia. 24 (2): 170–180. doi:10.1111/pan.12268. PMID 24118506.
- ^ "Pharmacokinetic Modeling of CT001 in Pediatric Patients". PAGE Meeting 2024. Retrieved 23 September 2024.
- ^ "PowerPoint Presentation - PAGE Meeting 2024". PAGE Meeting 2024. Retrieved 23 September 2024.
- ^ Nielsen, B.N. (2024). "Safety and tolerability of intranasal ketamine/sufentanil in pediatric patients". Acta Anaesthesiologica Scandinavica. 68 (5): 600–610. doi:10.1111/aas.14510. PMID 39155580.
- ^ "Cessatech receives positive opinion from EMA on PIP for CT001". MedWatch (in Danish). 15 November 2019. Retrieved 23 September 2024.
- ^ "EMA approves PIP for Cessatech's CT002". MedWatch (in Danish). 3 October 2023. Retrieved 23 September 2024.
- in-depth (not just brief mentions about the subject or routine announcements)
- reliable
- secondary
- strictly independent of the subject
Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.